topsalysin

July 1, 2019

Phase 3 Trial of Topsalysin, Potential Treatment for Localized Prostate Cancer, Planned for Europe

News

The European Medicines Agency (EMA) has approved Sophiris Bio’s design for a Phase 3 trial to evaluate the potential of topsalysin (PRX302), an investigative agent for localized prostate cancer. The ... Read more

September 10, 2018September 10, 2018

Patient Death in Phase 2b Prostate Cancer Trial Unrelated to Topsalysin, Sophiris Says

News

Topsalysin (PRX302), an investigative agent for localized prostate cancer, is unlikely to have caused the death of a patient in a Phase 2b trial testing the medicine, Sophiris Bio announced. A review of clinical ... Read more

June 5, 2017June 5, 2017

Sophiris to Begin Dosing Patients in Phase 2b Study of Topsalysin for Prostate Cancer

News

Sophiris Bio has received a green light to begin dosing patients in a Phase 2b U.S. clinical trial of topsalysin (PRX302) for prostate cancer. The go-ahead was in the form of a Federal ... Read more

January 6, 2017

Topsalysin Aiding Majority of Prostate Cancer Patients, Early Clinical Trial Results Show

News

Sophiris Bio Inc., recently released six-month biopsy data from the first seven prostate cancer patients treated with its drug candidate PRX302 (topsalysin) in a Phase 2a proof-of-concept clinical trial. PRX302 is being developed for ... Read more